Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELOVL1 | Q9BW60 | 2/20 | 0.58 |
| ▸ | RAB9A | P51151 | 2/20 | 0.58 |
| ▸ | NPC1 | O15118 | 1/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.56 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.53 |
| ▸ | ROCK1 | Q13464 | 4/20 | 0.53 |
| ▸ | MEN1 | O00255 | 3/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.52 |
| ▸ | WNT3A | P56704 | 1/20 | 0.52 |
| ▸ | PRKACA | P17612 | 1/20 | 0.52 |
| ▸ | CLK1 | P49759 | 1/20 | 0.52 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL436416 | 0.86 | WNT3A (0.69) | ELOVL1RAB9ANPC1CYP3A4ROCK1 | |
| SCHEMBL438712 | 0.86 | ELOVL1 (0.64) | ELOVL1RAB9ANPC1CYP3A4ROCK1 | |
| SCHEMBL438724 | 0.85 | ELOVL1 (0.58) | ELOVL1RAB9ANPC1CYP3A4ROCK1 | |
| SCHEMBL436506 | 0.84 | ROCK1 (0.53) | ELOVL1RAB9ANPC1CYP3A4ROCK1 | |
| SCHEMBL436414 | 0.84 | ROCK1 (0.64) | ELOVL1RAB9ANPC1CYP3A4ROCK1 | |
| SCHEMBL439244 | 0.84 | ELOVL1 (0.62) | ELOVL1RAB9ANPC1CYP3A4ROCK1 | |
| SCHEMBL439503 | 0.83 | CYP3A4 (0.64) | ELOVL1RAB9ANPC1CYP3A4ROCK1 | |
| SCHEMBL439696 | 0.81 | CYP3A4 (0.72) | CYP3A4ROCK1MEN1KMT2AROCK2 | |
| SCHEMBL436405 | 0.80 | WNT3A (0.68) | RAB9ANPC1CYP3A4ROCK1MEN1 | |
| SCHEMBL438705 | 0.79 | CYP3A4 (0.88) | RAB9ACYP3A4ROCK1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8278306-B2 | C-met protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-10-02 | — | — | US | disclosed |
| US-8278306-B2 | C-met protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-10-02 | — | — | US | disclosed |
| US-20120065213-A1 | C-MET PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-03-15 | — | — | US | disclosed |
| US-20120065213-A1 | C-MET PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-03-15 | — | — | US | disclosed |
| US-8058271-B2 | Selective inhibitors of rock protein kinase and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-11-15 | — | — | US | disclosed |
| US-8058271-B2 | Selective inhibitors of rock protein kinase and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-11-15 | — | — | US | disclosed |
| EP-2032562-B1 | SELECTIVE INHIBITORS OF ROCK PROTEIN KINASE AND USES THEREOF | VERTEX PHARMA (US) | 2010-08-25 | — | — | EP | disclosed |
| WO-2007133622-A2 | SELECTIVE INHIBITORS OF ROCK PROTEIN KINASE AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-11-22 | — | — | WO | disclosed |
| US-20070270386-A1 | Selective inhibitors of rock protein kinase and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED | 2007-11-22 | — | — | US | disclosed |
| US-20070270386-A1 | Selective inhibitors of rock protein kinase and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED | 2007-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070270386-A1 | Selective inhibitors of rock protein kinase and uses thereof | ROCK1, ROCK2, MYLK | ELOVL1 2798/4885RAB9A 696/4885NPC1 2801/4885 |
| US-20120065213-A1 | C-MET PROTEIN KINASE INHIBITORS | MET, PRKCH, MYLK | ELOVL1 3141/4885RAB9A 1217/4885NPC1 2213/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.